Nanomerics
29-39 Brunswick Square
London
NW1 1AX
United Kingdom
Tel: 44-0-20-3397-2183
Fax: 44-0-20-3397-2184
Website: http://www.nanomerics.com
About Nanomerics
Nanomerics are leaders in pharmaceutical nanotechnology. Our nanomedicines know-how and our proprietary technology platforms provide drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides.YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Andreas Schatzlein
CSO: Ijeoma Uchegbu
JOBS:
Please click here for.
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW NANOMERICS:
Tweets by Nanomerics
11 articles about Nanomerics
-
Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada
4/13/2023
Nanomerics Ltd., a private speciality pharmaceutical company announced that the Company had been granted patent protection in Canada for the ocular use of its Molecular Envelope Technology drug delivery system.
-
Nanomerics Awarded an MHRA Innovation Passport for OC134
8/31/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had received an Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency for its lead asset - OC134.
-
Nanomerics CSO Made Honorary Fellow of the Royal Society of Chemistry
7/20/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the company's Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK's Royal Society of Chemistry.
-
Meet Nanomerics CSO in Montreal This Summer - Nanomerics CSO to Give Plenary Lecture at Controlled Release Society Annual Meeting and Expo in Montreal on 13th July 2022
7/11/2022
Nanomerics Ltd ., a private speciality pharmaceutical company, today announced that Nanomerics' Chief Scientific Officer would be giving a plenary lecture at the Controlled Release Society Annual Meeting and Expo on Wednesday 13th July 2022.
-
Nanomerics Announces Quotient Sciences as its Clinical Trials Partner
3/28/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.
-
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
3/22/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence to Virpax Pharmaceuticals.
-
Better Brain Medicines - Nanomerics Announces Patents Granted in the US, Europe and Japan on the Nose to Brain Use of its Molecular Envelope Technology
3/14/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had been granted patent protection in multiple jurisdictions for brain delivery applications of its Molecular Envelope Technology.
-
Nanomerics Expands and Moves to New Laboratories
2/17/2022
Nanomerics Ltd., a private speciality pharmaceutical company and University College London spin out, announced that the Company had invested significantly in its operations, and moved to new laboratories and offices in North London.
-
Deaths from drug overdoses have been on an upward trajectory for years, but have experienced a notable increase since the early days of the COVID-19 pandemic.
-
Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology
5/24/2021
Nanomerics Ltd., a world leader in molecular engineered delivery technologies, announced the Company had been granted patent protection in multiple territories for the use of its Molecular Envelope Technology for ocular applications.
-
NEMUS Bioscience Signs Development Agreement With Nanomerics To Advance Ocular Formulation Of NB1111 For The Treatment Of Glaucoma Using Proprietary Molecular Envelope Technology (MET)
3/20/2017